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ABSTRACT    
  
 
Factor X deficiency is a rare bleeding disorder with an incidence of one in a million in 
the general population. Patients with the severe form of factor X deficiency suffer 
from serious bleeds occurring mainly into the joints and the muscle. In the two factor 
X deficient families currently looked after at the Haemophilia Comprehensive Care 
Centre, there are definite differences in the bleeding tendencies between and within 
family members. We hypothesize the differences in genetic mutations and the 
influence of cytokines to be responsible for these bleeding variabilities.  These factors 
were explored in our study. 
 
The study population included a total of fourteen members of the two families with 
factor X deficiency. Blood for factor X measurement, cytokine studies and genetic 
studies was collected in the Haemophilia Comprehensive Care Centre of the Charlotte 
Maxeke Johannesburg Academic Hospital. Each blood was processed according to 
the test to be performed. Factor X activity levels were measured using the factor X 
assay, and the information on each patient’s bleeding episodes was obtained from the 
Haemophiliac Clinic database. Cytokines were analyzed in all patients using the 
ELISA kits from Biosource. Factor X gene was amplified using PCR and sequenced 
with Spectrumedix SCE 2410. 
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For cytokine studies, high levels of IL-1beta and TNF-alpha were observed in 
frequent bleeding patients compared to infrequent bleeders. These cytokines are 
known to be involved in acute inflammatory process leading to cellular infiltrate and 
joint swelling. This results in synovitis and the creation of massive joint bleeding. The 
low levels of IL-1beta and TNF-alpha detected in infrequent bleeding patients appear 
to be related to the high levels of IL-1Ra and IL-10. These anti-inflammatory 
cytokines are known to inhibit the inflammatory synovitis and lessen the severity of 
joint bleeding. 
 
For genetic studies, differences were observed between the amino acid sequence of 
the three frequent bleeding patients and the consensus. In addition, a novel mutation 
Cys350Phe was detected in two of these patients. This mutation is characterized by 
very low factor X levels which sometimes are not detectable in circulation. The 
substituted cystine is known to cause defect in the substrate binding, leading to the 
lost of enzyme activity. From these findings we have concluded that the origin of the 
heterogeneity of bleeding in factor X deficiency is multifactorial, cytokines and 
genetic mutations seems to have a role in determining the clinical manifestations of 
the factor X deficient patients. 
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CHAPTER   I 
 
1.1 INTRODUCTION 
 
Coagulation factor X, is a vitamin K-dependent serine protease which plays a crucial 
role in blood clotting as the first protein in the common pathway of coagulation 
cascade (Figure 1). Factor X (FX) is also known as the Stuart-Prower factor after the 
index cases in which this deficiency was first described (Hougie and Barrow 1957; 
Telfer and Denson 1956). Factor X deficiency results in a life long bleeding diathesis 
characterized by bleeding into joints, mucous membranes and other sites after 
haemostatic challenges. This deficiency could be a consequence of the factor X 
genetic mutations, or acquired causes resulting in quantitative or qualitative 
abnormalities of the factor X protein (Uprichard and Perry 2002). 
 
 
 
Figure 1. Schematic showing the coagulation cascade leading to fibrin formation. A deficiency or 
dysfunction of coagulation factor X compromises both the intrinsic and extrinsic pathways of 
coagulation (Bowen 2002). 
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In factor X deficiency, the clinical phenotype correlates poorly with the laboratory 
phenotype and factor X coagulation activity (Sucker et al., 2006). Therefore, factor X 
cannot be unambiguously used as the basis for the classification of clinical severity. In 
previous studies, the clinical phenotype of factor X deficiency was generally 
described only as severe, mild or asymptomatic depending on bleeding symptoms 
(Sucker et al., 2006; Takabe et al., 2004). 
 
In the two factor X deficient families currently looked after at the Haemophilia 
Comprehensive Care Centre of the Charlotte Maxeke Johannesburg Academic 
Hospital, there are definite differences in the bleeding tendencies between and within 
families. A number of factors could be plausible reasons for these phenotypic 
discrepancies, and these include different genetic mutations in the factor X gene, 
different factor X protein levels or the influence of other epigenetic factors such as 
cytokines.  
 
The recurring joint bleeding in factor X deficiency result in the development of joint 
destruction known as haemophilic arthropathy (Bae et al., 2009; Meenakshi et al., 
2008). The bleeding is caused by synovitis which is characterized by neo-
vascularization and villous formation inside the joint. This condition sets up a vicious 
cycle of bleeding causing synovitis resulting in more bleeding (Bae et al., 2009; 
Meenakshi et al., 2008). 
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After the onset of active synovitis synovial bleeding may not be related only to 
clotting factor X deficiency but, also to pre-existing vascular damage and 
inflammation (Ehrenforth et al., 1992; Meenakshi et al., 2008). There is evidence to 
suggest that iron may play a central role in the development and sustenance of 
synovitis. This involved the release of cytokines which were suggested to perpetuate 
this condition and lead into massive joint bleeding (Meenakshi et al., 2008; Suchitra 
2008).  
 
In human in vitro and in animal in vivo models, it was shown that a limited number of 
short-term joint haemorrhages could induce lasting changes to cartilage matrix 
turnover (Valentine et al., 2007). This eventually led to cartilage destruction. The 
current opinion is that chronic synovitis is the main factor for progressive cartilage 
destruction as a result of joint bleeds (Roosendaal and Lafeber 2003). 
 
It was reported that the initial and irreversible changes in cartilage matrix metabolism 
were independent of synovial inflammation (Hakobyan et al., 2004). The primary 
adverse changes in cartilage were found to be induced by the combination of 
mononuclear cells (MNC) plus red blood cells (RBC) (Hakobyan et al., 2004). 
However, the mechanism played by MNC plus RBC in the pathophysiology of blood-
induced cartilage damage is still unclear (Hooiveld et al., 2003; Wen et al., 2002; 
Hoots 2007).  
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Currently, it is known that the blood MNC in the joint cavity produce interleukin -
1beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha) after a joint bleed (Lotz 
2001). The production of these cytokines was found to be independent of an 
inflammatory response (Hoots 2007; Lotz 2001). The concurrent presence of RBC 
was suggested to play a role in RBC-derived toxicity. It was argued that haemoglobin 
iron may result in oxidative stress, which may cause damage to chondrocytes (Dunn 
et al., 2005; Harris et al., 2006). This was based on the fact that iron can act as a 
catalyst for the Fenton reaction in which hydroxyl radicals are formed from hydrogen 
peroxide. Hydrogen peroxide produced by chondrocytes was found to be increased 
after stimulation with IL-1beta and TNF-alpha. This has been suggested to have an 
adverse effect on cartilage matrix turnover (Donadel 2006; Dunn et al., 2005; Harris 
et al., 2006).   
 
The cytokine balance and receptor antagonists might be determinants not only for 
initiation and progression, but also for the clinical expression of synovitis (Meenakshi 
et al., 2008). It was reported that during synovitis, a complex inflammatory response 
was developed. It was found that there was a local imbalance between the expression 
of interleukin -1beta (IL-1beta), tumor necrosis factor -alpha (TNF-alpha) and 
interleukin -1receptor antibody (IL-1Ra). This was associated with joint destruction 
and the clinical outcome of bleeding (Meenakshi et al., 2008; Saski et al., 2007; 
Suchitra 2008). 
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Association of pro-inflammatory and anti-inflammatory cytokines have not been 
studied in factor X deficiency. Literature on this association is therefore scanty.         
To date, there are no published studies in the mainstream journals exploring the 
cytokine levels as a possible explanation for the phenotypic discrepancy in patients 
with factor X deficiency. We hypothesized that, in these two families of factor X 
deficient individuals, reasons for their variation in bleeding phenotype could be 
multifactorial with genetic, protein levels as well as cytokines possibly contributing.  
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1.2 Aim of the study 
 
The aim of this study is to establish if there are any associations between coagulation 
factor X activity levels, bleeding frequencies, genotypic features and cytokine profiles 
in factor X deficient patients. 
 
1.3 Objectives 
 
 To determine the clotting factor X activity and phenotypic presentations in 
factor X deficiency. 
 To determine the cytokine profiles (IL-1beta, TNF-alpha, IL-10, IL-18, and 
IL-1Ra) of factor X deficiency. 
 To sequence the factor X gene in factor X deficiency. 
 To establish if there are any associations between coagulation factor X 
activity levels, clinical manifestations, genotypic features and cytokine 
profiles in factor X deficiency. 
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1.4. LITERATURE REVIEW 
 
1.4.1 Factor X gene 
 
 Factor X is encoded by a gene, which has 8 exons located on chromosome 13. Each 
exon encodes a specific peptide of the factor X preproprotein (Figure 2). Exon I 
encodes the signal peptide, exon II encodes the propeptide and glutamic acid (Gla) 
domain, exon III encodes the aromatic amino acid stack, exons IV and V each code 
for the epidermal growth factor-like regions (EGF), exon VI encodes the activation 
domain, and exons VII and VIII encode the catalytic domain (Millar et al., 2000). The 
causative molecular defects of factor X deficiency are heterogeneous. To date, 
approximately 87 factor X mutations have been described. The majority of these 
mutations are missense with a few splicing frameshift and large deletions (ISTH 
factor X database, 2009). 
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Figure 2. Schematic representation of organization of the human factor X gene and its encoded 
polypeptide. The upper part of the illustration represents the factor X gene with the eight exons 
shown by filled boxes. The positions of the first and last nucleotides of each exon are shown. The 
lower part of the illustration shows the polypeptide structure and the various functional domains 
encoded. (Residue +1 is the first amino acid of the mature protein). Residue – 29 indicates the site 
of probable cleavage by signal peptidase. The light chain is encoded by residues + 1 to 139 and 
the heavy chain by residues 143 to 448. The connecting tripeptide is located between residues 140 
and 142 and the activation peptide residues within the heavy chain at residues 143-195. 
Activation of factor X occurs through cleavage at Arg 194-Ile195. Residue 427 shows the site of 
cleavage of factor X that generates factor Xa. His 236, Asp 282 and Ser 379 are the residues 
which constitute the catalytic triad (Divi et al., 2002). 
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1.4.2 Factor X protein  
 
Factor X is a product of hepatocytes. Before its secretion, this protein undergoes 
proteolytic processing in the endoplasmic reticulum. This produces the circulating 
factor X as a two-chain polypeptide linked with a disulphide bond. Factor X is 
activated by a complex of negatively charged phospholipids, factor IXa and factor 
VIIIa or by membrane-bound complex of factor VIIa and tissue factor. Factor X can 
also be activated by a component of Russell's viper venom. In each case, activation of 
factor X is accomplished by proteolytic cleavage and subsequent removal of the 
activation peptide (Mizuno et al., 2001). 
 
Once it is activated, factor X with its cofactor (factor V) catalyses the conversion of 
prothrombin to thrombin. This reaction requires the negatively charged phospholipids 
and calcium ions. A deficiency or dysfunction of either factor V or factor X 
compromises the conversion of prothrombin, and the ensuing steps of the coagulation 
cascade resulting in inefficient or non-existent fibrin deposition. Therefore, the 
fundamental biochemical lesion underlying the factor X deficiency is the failure to 
generate thrombin as a result of a deficiency of coagulation factor X. Levels of 10-20 
IU/dl is sufficient to stop bleeding (Hsiao-Ling et al., 2001). 
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1.4.3 Factor X deficiency 
 
Inherited factor X deficiency (FXD) is a very rare recessive coagulation disorder. 
Patients with factor X deficiency present with bleeding disorders of variable 
magnitude. Dewerchin et al. (2000) showed that FX-/- knockout mice die in utero or 
days after birth, indicating that the complete absence of factor X is incompatible with 
life. This explains the extremely low incidence of homozygous FXD (1:1 000 000) in 
the general population (Dewerchin et al., 2000). The prevalence of FXD is much 
greater among the populations in which consanguineous marriage is common (for 
example most middle countries such as Iran). In such populations, the prevalence of 
heterozygous FXD is about 1: 500, but this is usually asymptomatic (Masood et al., 
2005). 
 
Factor X deficiency is suspected when there is a prolonged activated partial 
thromboplastin time (aPTT) and prothrombin time (PT). The diagnosis of factor X 
deficiency is confirmed by measuring factor X levels, which can be done either by 
clotting or immunological assay. (Masood et al., 2005; McMullen et al., 1983). 
Inherited factor X deficiency must be differentiated from various acquired causes 
such as systemic amyloidosis. Factor X deficiency that occurs in this disorder can 
result from selective binding of factor X to the amyloid fibrils. This can be 
erroneously recognized as the presence of an inhibitor (Masood et al., 2005; Perry 
1997). 
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1.4.4 Genetics of factor X deficiency 
 
Congenital deficiencies of coagulation factor X usually arises from missense 
mutations. In such mutations, the substitution of one nucleotide for another results in 
the translation of a different amino acid from that of the wild type protein. If the 
nucleotide substitution results in an amino acid which does not significantly alter the 
protein structure or function, then the individual will not demonstrate a clinical 
deficiency. However, if the new residue does alter the structure and the function of the 
protein, then deficiency will follow and the individual will exhibit a bleeding disorder 
(Perry 1997). 
 
A number of restriction fragment length polymorphisms within the factor X gene have 
been identified. Such polymorphisms are of potential use in tracking mutant alleles in 
families with factor X deficiency (Cooper and Tuddenham 1997; ISTH factor X 
database, 2009). Most of the deletion mutations results in impaired protein synthesis 
or in synthesis of unstable or dysfunctional proteins. These variants may affect factor 
X function in several ways. Activation through the tissue factor pathway may be 
affected when the mutations are located in the Gla domain. This is detected in 
Glu7Gly (St. Louis II) (Rudolph et al., 1996), Glu14Lys (Vorarlberg) (Herrmann et 
al., 2001) and Ser379Lys (Watzke et al., 1990). These mutations are predicted to 
result in a reduced affinity for calcium which plays an important role in activation of 
factor X.  
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Activation through factor IXa is affected by Thr318Met (Roma) (Marchettgi et al., 
1995), Arg139Cys (Wenatchee I) (Kim et al., 1995) and Arg139Ser (Kurayochi) 
(Lijima et al., 2001). It was shown that these mutations prevent the removal of the 
activation peptide (Lijima et al., 2001). This then results in dysfunctional protein 
which is rapidly degraded in plasma. Activation of factor X through Russell's viper 
venom is almost intact in the Pro343Ser (Friuli) (James et al., 1991). This mutation 
was predicted to form a new hydrogen bond between Ser343 and Thr318. This affects 
the tertiary structure of the region and its catalytic potential (James et al., 1991).   
 
Missense mutations may also affect synthesis or secretion, thus producing 
dysfunctional factor X (Racchi et al., 1993; Millar et al., 2000).This is detected with 
Gly-20Arg (Santo Domingo) (Racchi et al., 1993), Thr-2Met and the Val298Met 
(Stuart mutation)(Millar et al., 2000). In these mutations factor X is synthesized 
normally and translocated into the endoplasmic reticulum, but not processed by the 
signal peptidase. It was argued that these mutations lead to a complete loss of 
translation of FX molecule, because the codon GTC cannot initiate translation 
(Miyata et al., 1998). 
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The clinical manifestations of FXD may also be influenced by epigenetic factors. This 
arises from family studies that show a discrepancy in bleeding between siblings with 
same genetic mutation (Kram et al., 2007; Van Den Berg et al., 2007). These authors 
have pointed out the role of genetically determined characteristics of the immune 
response, fibrinolysis and pharmacokinetics as factors that might explain the 
discrepancy of bleeding. These factors are yet to be explored (Musacchio et al., 2009; 
Kram et al., 2007; Van Den Berg et al., 2007). 
 
1.4.5 Clinical manifestations of factor X deficiency 
 
Patients with FXD may present with a bleeding tendency at any age, although the 
more severely affected ones present early in life with umbilical-stump bleeding. 
Haemathroses, severe post operative haemorrhage and central nervous system 
haemorrhage have also been reported (Laffan and Manning 2001). More unusual 
bleedings are intestinal bleeding, urinary tract bleeding and soft tissue bleeding. In 
individuals homozygous for moderate or mild deficiencies of factor X, bleeding is 
less common usually occurring only after trauma or after surgery. Such patients are 
reported to experience easy bruising as the only clinical manifestation (Laffan and 
Manning 2001). 
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The presence of chronic synovitis in joints of FXD patients results from recurrent 
joint bleeds (Wiedel 2002). This is an inflammatory condition characterized by villous 
formation and markedly increased vascularisation. This state leads into pannus 
formation and destructive arthritis which marks the onset of arthropathy. The chronic 
synovitis leads into maximum limitation of motion. After the onset of active synovitis 
synovial bleeding may not be related only to clotting  factor X deficiency but, also to 
pre-existing vascular damage and inflammation which is often difficult to control 
clinically (Figure 3)( Fei-Qiu et al., 2002; Wiedel 2002). 
 
The acute bleeding episode initiates the onset of a series of recurrent joint bleedings. 
This creates a circle of bleeding→synovitis→bleeding (Fei-Qiu et al., 2002). 
However, the risk factors for the progression of these joint bleeds are not well 
defined. There is evidence to suggest that iron may play a central role in the 
pathogenetic process causing changes at the molecular level. This involves the 
production of cytokines which were suggested to perpetuate the chronic inflammatory 
state (Meenakshi et al., 2008; Roosendaal and Lafeber 2003; and Suchitra 2008). 
 
More studies are needed to try to understand the mechanisms involved in the 
pathogenesis of these bleeding series. This may provide insight into the discrepancy 
of bleeding in both haemophiliacs and factor X deficient patients. Management of 
chronic arthropathy remains a problem for most coagulation disorders. Such data 
might be used to facilitate the development of monoclonal antibodies to inhibit all the 
components that uphold the process (Suchitra 2008).  
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Figure 3. Schematic representation of synovial changes in hemophilic joint disease. A hemophilic 
joint depicting hemarthroses leading to the development of synovitis. The red lining depicts 
synovial hyperplasia and hypertrophy progressing to cartilage erosion and arthropathy (Suchitra 
2008). 
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1.4.6 Inflammatory cytokines and synovial bleeding 
 
Traditionally it is thought that recurrent joint bleeds stimulates synovial proliferation 
and the release of hydrolytic enzymes (Suchitra2008). These enzymes along with 
elevated levels of cytokines help in maintaining the inflammatory response in the 
synovium. Hence, synovitis is thought to be degenerative and inflammatory in nature 
(Berntorp et al., 2003; Fischer et al., 2002). 
 
Bleeding into the joint space exposes synovial cells to blood and all its components 
including iron (Feldman et al., 2006; Fischer et al., 2003). Suchitra (2008) studied a 
central role for iron in the development of hemophilic synovitis. Iron deposits were 
observed in the cytoplasm of the lining synovial cells along with neo-visualization. It 
was further observed that when iron loaded tissues were cultured in vitro they 
synthesized more pro-inflammatory cytokines such as interleukin-18 (IL-18), IL-
1beta and TNF-alpha compared to normal appearing synovial tissue (Harris et al., 
2006; Hilberg et al., 2003; Suchitra 2008). 
  
Haemophiliacs with synovitis were also found to exhibit a fivefold increase in 12 
circulating angiogenesis-related cytokines compared to individuals with a bleeding 
disorder without joint disease (Beeton et al., 2000; Harris et al., 2006; Suchitra 2008). 
Likewise, plasma vascular endothelial growth factor (VEGF) and matrix 
metalloproteinases were significantly elevated in those subjects compared to the non-
joint disease groups (Beeton et al., 2000; Harris et al., 2006; Suchitra 2008).  
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Some aspects of haemophilic synovitis remain unclear. Firstly, mediators 
participating in cartilage breakdown are uncertain. Secondly, the way in which iron 
enters chondrocytes is not yet explained (Suchitra 2008). An understanding of these 
mechanisms may provide insight into the pathogenesis of these bleeding series. In 
both rheumatoid and haemophilic arthritis microbleeding is well recorded (Harris et 
al., 2006). The synovial iron deposition was found to correlate closely with the extent 
of joint destruction and was associated with poor prognosis (Suchitra 2008).   
 
A possible sequence of events in haemophilic arthritis may be caused by intra-
articular bleeding (Fischer et al., 2002). This provokes a nonspecific inflammatory 
response and cause macrophage to accumulate around synovial iron deposits (Suchitra 
2008). The macrophages then release cytokines, and stimulate production of latent 
matrix metalloproteinases (Suchitra 2008).With repeated joint bleeding, the synovium 
proliferates and start producing a cycle of synovitis →bleedings →synovitis (Suchitra 
2008). 
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Currently, most synovitis studies are reporting IL-1beta and TNF-alpha as cytokines 
that causes an increase in the synthesis of nitric oxide (NO) and matrix 
metalloproteinases (MMPs) (De Jager et al., 2007; Del Porto et al., 2007; Lerner 
2006; Suchitra 2008). The NO produced in the inflamed joint was found to contribute 
to the peri-articular bone-loss, leading into massive pain and joint bleeding (De Jager 
et al., 2007; Del Porto et al., 2007; Lerner 2006; Suchitra 2008). The matrix 
metalloproteinases (MMPs) were found to be enzymes that break down collagen from 
the cartilage (Edwards 2005). Other authors have reported the MMPs to be involved 
in angiogenesis and in recruitment of some pro-inflammatory cytokines that 
contribute in excessive destruction of cartilage (Clavel and Bessis 2007; Folkman and 
Shing 1992). 
 
Direct evidence was observed for the involvement of angiogenesis in the development 
and sustenance of haemophilic synovitis (Harris et al., 2006; Suchitra 2008). 
Histological sections of synovial tissue from patients with haemophilic synovitis were 
found to be highly vascularized and contained a high number of inflammatory cells, 
predominantly macrophages. These sections were co-localized with secreted pro-
angiogenic cytokines including vascular endothelial growth factor (VEGF), tumor 
necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta) and interleukin-18 
(IL-18) (Harris et al., 2006; Hilberg et al., 2003; Ovlisen et al., 2009). 
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The elevated levels of interleukin-18 (IL-18), TNF-alpha and VEGF were found to be 
dominant activators of angiogenesis. This condition resulted in the formation of 
premature blood vessels that leaks into the joint and perpetuates the synovitis and 
joint bleeding (Figure 4) (Clavel and Bessis 2007; Dai et al., 2004; Suchitra 2008). In 
the study by Dai et al. (2004), IL-18 was found to promote synovitis through a 
mechanism shown to be distinct from IL-12. Interestingly, IL-18-treated mice were 
reported to produce significant
 
amount of TNF-alpha and IL-1beta. It was then 
suggested that IL-18 might have the up regulatory role in the production of the two 
cytokines (Dai et al., 2004).  
 
The pathogenesis of joint disease in coagulation disorders seems to be multifactorial 
with changes occurring in the synovium, bone, cartilage and blood vessels associated 
with the affected joints (Ostergaard et al., 2001; Ovlisen et al., 2009). Iron may be 
central to these processes, however all these processes may be occurring concurrently 
rather than sequentially (Ostergaard et al., 2001). Hence, prevention of joint bleeds 
still seems to be crucial in mitigating the development and progression of joint disease 
(Ostergaard et al., 2001; Suchitra 2008).  
 
Circulating angiogenic cytokines may provide effective means of detecting early 
synovial proliferation and identifying candidates for early intervention with therapy 
(Ostergaard et al., 2001; Ovlisen et al., 2009).Ultimately, anti-angiogenic agents may 
provide a novel preventative treatment strategy for arthropathy in coagulation 
disorders (Ostergaard et al., 2001; Suchitra 2008). 
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Figure 4. Schematic representation of chronic arthropathy induced by IL-18, TNF-alpha and 
VEGF. This creates massive haemorrhage and joint degradation. The up regulation of these 
cytokines is associated with angiogenesis. This results in the formation premature blood vessels 
that leaks into the joint and worsening the synovitis (http:// www.google.co.za/ image/role of IL-
18 in joint inflammation Date of last access 25 June 2009). 
 
 
 
 
 
 
 
 
 
 
IL-18, TNF-alpha & VEGF 
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1.4.7 Anti-inflammatory cytokines and synovial bleeding 
 
Interleukin-10 (IL-10) and interleukin-4 (IL-4) are modulatory cytokines that have a 
suppressive effect on TNF-alpha and IL-1beta in vitro (De Wall et al., 1991; Yoshiki 
et al., 2008). They suppress cytokine synthesis by different intracellular mechanisms. 
IL-4 enhances mRNA degradation of TNF-alpha and IL-1beta, while IL-10 inhibits 
nuclear factor kappa B (NF-кB) (Schalijo et al., 2009; Yoshiki et al., 2008; Wang et 
al., 1995). The NF-кB is the intracellular region known to promote the expression of 
numerous inflammatory genes (Schalijo et al., 2009).  
 
It has been shown that IL-4 and IL-10 stimulate the production of cytokine inhibitors 
such as interleukin-1receptor antagonist (IL-1Ra) and soluble tumour necrosis factor 
receptor (TNFR). The up regulation of these anti-inflammatory cytokines was shown 
to have a positive effect on synovitis (Erik et al., 1998; Jenkins et al., 1995; Shepherd 
and Nicklin 2005). Sustained treatment with IL-4 was shown to suppress the chronic 
synovitis and induced the up regulation of IL-1Ra. Elevated levels of IL-10 were 
found to have the same effect, but the combination therapy with IL-4 has been found 
to induce a more profound suppression with a major protective effect against 
arthropathy (Erik et al., 1998; Schalijo et al., 2009). 
 
 
 
 
 
 
  22 
The IL-1Ra inhibits the actions of IL-1beta by binding to the type I IL-1 receptor (Pan 
et al., 2000). When delivered systemically as recombinant protein, IL-1Ra was able to 
prevent the onset of experimental synovitis and reduce the severity of arthropathy 
(Pan et al., 2000). One study has reported IL-1Ra to have an anti-angiogenesis effect 
in cancer patients (Dganit et al., 2003). It remains to be seen whether this cytokine 
might have a significant impact in treating synovitis induced by haemathrosis in FXD 
patients and in haemophiliacs.  
 
Anticytokine therapy offers new hope to those suffering from synovial bleeding (Bae 
et al., 2009). The prospect of specifically targeting the effects of key pro 
inflammatory cytokines in synovitis network may represent a new therapeutic era 
(Musacchio et al., 2009). From the evidence presented, it could be speculated that all 
frequent bleeding patients might present with significant high levels of pro 
inflammatory cytokines (TNF-alpha, IL-1beta and IL-18). These cytokines were 
shown to be involved in acute inflammatory process leading to cellular infiltrate and 
joint swelling (De Jager et al., 2007).This enhances synovitis cycle and leads into 
massive joint bleeding (Ovlisen et al., 2009). On the other hand, infrequent bleeding 
patients might present with high levels of IL-10 and IL-1Ra. This inhibits the 
inflammatory synovitis and lessens the frequency and severity of joint bleeding (Erik 
et al., 1998; Schalijo et al., 2009). 
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1.4.8 Treatment for factor X deficiency  
 
Repeated bleeds into the joints of factor X deficiency could be prevented by the 
infusion of factor X concentrates on a daily or weekly schedule depending on the 
activity levels and bleeding phenotype (Auerswald 2006; Nuss et al., 2000). In those 
patients who developed antibodies against the infused factor X, isotopic synovectomy 
can provide relief from repeated joint bleeds (Berntorp and Michiels 2003; Nuss et al., 
2000). However, the timing at which this can be applied is still not well-defined. 
Newer strategies to identify early joint disease through the use of serological markers 
are needed (Berntorp and Michiels 2003; Nuss et al., 2000; Yoshiki et al., 2008). 
 
The treatment options for bleeding in patients with congenital FX deficiency include 
the administration of fresh-frozen plasma, or prothrombin complex concentrates 
(PCCs) that contain FX. The administration of fresh frozen plasma may be associated 
with complications. This procedure carries a high potential of infections, with 
hepatitis viruses and human immunodeficiency virus (HIV) being the most reported 
(Auerswald 2006; Nuss et al., 2000).   
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Prophylaxis is generally not required in patients with factor X deficiency, except in 
the most severe cases of bleeding where residual factor X activity is less than 1%, or 
when bleeding symptoms and severity are similar to those observed in patients with 
severe haemophilia A (Auerswald  2006; Nuss et al., 2000). However, very low 
residual factor X activity (1%) may not necessarily be associated with severe 
bleeding. These observations have been made in patients from the same family and in 
relatives with the same genetic mutation (Auerswald 2006; Kram et al., 2007; Van 
Den Berg et al., 2007). Therefore, the heterogeneity in bleeding tendency remains 
widely open for investigations. 
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CHAPTER 2 
 
PATIENTS AND METHODS 
 
2.1 Study design 
 
This was a cross sectional, uncontrolled study of two unrelated families with factor X 
deficiency. 
 
2.2 Study population and Sample size 
  
The study population included a total of 14 members of two families with factor X 
deficiency currently attending the Haemophilia Comprehensive Care Centre at 
Charlote Maxeke Johannesburg Academic Hospital. 
  
 Patients were provided with a written patient information leaflet, and were 
verbally informed about the aim, objectives and procedures to be employed in 
the study. 
 Patients were required to sign a consent form. 
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2.3 Blood sample collection  
 
Blood for the factor X measurement, cytokine studies and genetic studies was 
collected in the Haemophilia Comprehensive Care Centre. Each blood sample was 
processed according to the test to be performed. For factor X assay, the samples were 
collected in citrate tubes and centrifuged at 3500 g for 20 minutes and the resulting 
plasma stored at -70 
o
C if not analyzed immediately. For cytokine studies, the samples 
were collected in tubes without anticoagulant and centrifuged at 3500 g for 20 
minutes and the resulting serum stored at -70
o
C until analyzed. For genetic studies, a 
buffy coat was prepared from an EDTA blood sample and stored at -70
 o
C  prior to 
analysis. 
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2.4 Sample analyses 
 
2.4.1 Cytokine studies   
     
The ELISA kits from BioSource were used for the quantitative determination of       
IL-1beta (BioSource,IL-1beta Europe,SA),TNF-alpha (BioSource,TNF-alpha Europe, 
SA), IL-10 (BioSource, IL-10 Europe, SA ), IL-18 (BioSource, IL-18  Europe, SA ) 
and IL-1Ra (BioSource, IL-1Ra Europe, SA).These kits uses the same experimental 
procedure with the only difference being the microtiter plate provided.  
 
Principle  
 
To detect the quantity of cytokine, purified antibody specific for the measured 
cytokine is linked chemically to an enzyme. Standards and samples react with 
captured monoclonal antibody (Mab 1) coated on the microtiter well and with a 
biotinylated monoclonal antibody (Mab 2). After an incubation period allowing the 
formation of a sandwich, an enzyme Streptavidin -Peroxidase is added and this binds 
to the biotinylated antibody. The unbound enzyme is removed by washing and a 
substrate solution is added. This induces an enzyme catalyzed reaction. This reaction 
is stopped with the addition of stop solution and the microtiter plate is then read at 
450nm.The amount of colour change is determined calorimetrically by measuring the 
absorbance which is proportional to the concentration of the measured cytokine. A 
standard curve is plotted and the concentration of the measured cytokine is 
determined by interpolation from the standard curve.  This basic assay is shown in 
Figure 5. 
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Figure 5.Schematic showing of ELISA. The amount of substrate turnover is determined 
colorimetrically by measuring the absorbance which is proportional to the concentration of the 
measured cytokine (BioSource, Europe, SA).  
READ ABSORBANCE AT 450NM 
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Sample and reagent preparation 
 
Stop solution, substrate reagent, microtiter plate, and assay diluents were ready to use 
in all the kits. 1X washing solution was prepared by diluting 100ml of 25 X washing 
solution with 2400ml of distilled water. HRP-conjugate solution was diluted in a 
1:101 ratio with conjugate diluent. Standards were prepared after reconstituting the 
calibrator specific for the measured cytokine with 1ml of assay diluent.The 2500pg/ml 
of the calibrator was then serially diluted as shown in the table. 
 
 
Procedure 
 
Hundred and fifty micro liters (150μl) of prepared standards and samples were 
pipetted into a new 96 well polyvinyl plate in the same order as the assay to be run. 
All samples and standards were prearranged in the polyvinyl plate. Hundred micro 
liters (100µl) of each sample was transferred to the appropriate antibody coated wells 
simultaneously using a multi channel pipette. The plates were then incubated for 30 
minutes. This incubation step ensured that the measured cytokine bind to the coated 
monoclonal antibody. After incubation, the content of each well was discarded and 
the plates were washed four times with wash solution.  
 
Standard 
concentration 
IL-18/IL-1Ra/TNF-alpha/IL-1beta/IL-10 Assay 
Diluent 
1000pg/ml 200µl of 2500pg/ml standard 300µl 
400 pg/ml 200µl of 1000pg/ml standard 300µl 
160 pg/ml 200µl of 400pg/ml standard 300µl 
64 pg/ml 200µl of 160pg/ml standard 300µl 
25.6 pg/ml 200µl of 64pg/ml standard 300µl 
0.0 pg/ml  300µl 
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Hundred micro liters (100μl) of diluted conjugate reagent (biotinylated monoclonal 
antibody) and Streptavidin-Peroxidase were added followed by 60 minutes incubation 
at room temperature. This incubation step completed the sandwich and the attachment 
of Streptavidin-Peroxidase to the biotinylated monoclonal antibody. The supernatant 
content of each well was discarded and the plates were washed three times with wash 
solution. Hundred micro liters (100μl) of substrate reagent was added to each well 
followed by 30 minutes incubation. During this incubation, the enzyme induced a 
coloured reaction to its substrate. This reaction was stopped by 100µl of stop solution. 
The plates were then measured at 450nm using a micro plate reader. 
 
Interpretation of results 
 
The absorbencies of the standards were used to plot a standard curve. A straight line 
graph was obtained and results for each cytokine were extrapolated from the 
appropriate graph. An example is presented below (Figure 6). 
 
 
Figure 6. Straight line graph obtained from IL-10 standards. Sample results were extrapolated 
from this graph. 
 
                       Concentration  of IL-10  (pg/ml) 
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2.4.2 Determination of coagulation factor X  
 
The factor X assay was used for the quantitative determination of coagulation factor 
X activity levels (Schafer 2007).  
 
Principle  
 
The factor X assay relies upon measuring the degree of correction of the prothrombin 
time (PT) when patient plasma is added to normal reference plasma. These results are 
obtained from an activity curve drawn from dilutions of normal reference plasma and 
factor X deficient plasma. 
 
Sample and reagent preparation 
 
The factor X deficient plasma was reconstituted with 1ml of distilled water and 
allowed to equilibrate for 10 minutes. The same procedure was done with assayed 
reference plasma (Pentapharm, Basel, Switzerland). The assayed reference plasma 
and factor X deficient plasma were diluted into 1:10, 1:100 and 1:1000 using the 
Owrens buffer. The procedure is as follows. 
 
1:10 0.9 ml of Owrens buffer + 0.1 ml of  reference plasma/test plasma 
1:100 9.9 ml of Owrens buffer + 0.1 ml of the reference plasma/test plasma 
1:1000 9.99 ml of Owrens buffer + 0.01 ml of the reference plasma/test plasma 
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Procedure 
 
Thirty microlitres (30µl) of factor X deficient substrate (Pentapharm, Basel, 
Switzerland) was mixed with 30 µl of the diluted reference plasma. The tubes were 
incubated at 37°C for 30 seconds and vipera russelli-platelet substitute (Pentapharm, 
Basel, Switzerland) was added to activate factor X. The venom of vipera russelli 
activates factor X directly, and so it will detect deficiencies of factor X, factor V, 
prothrombin and fibrinogen. However, if factor X deficient plasma is used as a 
substrate, then the assay will be specific for factor X. After 30 seconds, clotting was 
initiated by the addition of 0.2 ml of 0.025M Calcium Chloride. The time for clot 
formation was recorded. This procedure was repeated using 30µl of patient plasma 
added to normal reference plasma. 
 
Interpretation of results 
 
The clotting times of the test and assayed reference plasma were plotted against the 
concentration of factor X on a double-log graph paper, taking the 1: 10 dilution as 
equivalent to 100% of the normal activity. A linear plot was obtained and the patient’s 
lines were parallel to the reference graph .A vertical line was drawn from the dilution 
that represents 100% of normal reference. This line was drawn until it intercepts the 
plasma sample being assayed. This vertical line was then dropped until it intercepts 
the X-axis. The activity level was read at that point. This is well presented in Figure 7. 
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Figure 7.The graph above shows the results of a factor X assay with varying factor X levels. The 
red line represents the reference plasma and green line represents the test samples. Results were 
extrapolated from the x-axis and multiplied by the dilution factor 100. 1/2 dilution was assigned a 
value of 50 IU/dl (50%), 1/4 dilution was assigned a value of 25 IU/dl (25%) and 1/5 was assigned 
a value of 20 IU/dl (20%) (Schafer 2007).  
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2.4.3 DNA extraction 
 
DNA was extracted using a Nucleon Resinant kit from Amersham. (Nucleon® 
BACC2 kit, GE Health Care   Europe- Amersham).  
 
Principle  
 
The system from Amersham was designed to give high yields of pure DNA from 
blood, cultured cells and hard tissue or paraffin sections. The procedure has been 
optimized to give maximum recoveries of high molecular weight DNA using a low 
shearing protocol. The principle includes cell lyses, deproteinisation, extraction and 
precipitation. 
 
Procedure 
 
Nine hundred microlitres (900 μl) of EDTA blood was transferred to the 1.5 ml micro 
tubes. Three hundred and fifty micro liters (350 μl) of reagent A (sodium perchlorate) 
(Nucleon® BACC2 kit, GE Health Care Europe-Amersham) was added. The mixture 
was centrifuged at 600 rpm for 5minutes. This step lysed the cells. The supernatant 
was removed and 700 μl of sodium perchlorate (Nucleon® BACC2 kit, GE Health 
Care Europe- Amersham) was added to the pellet and centrifuged again at 600 rpm 
for 5 minutes.  
 
 
  35 
Six hundred micro liters (600μl) of reagent B (chloroform) (Nucleon® BACC2 kit, 
GE Health Care Europe- Amersham) was added and the tubes were inverted 7 times. 
This step removed the proteins (histones) from pellet. Hundred and fifty micro liters 
(150μl) of Nucleon Resin suspension (Nucleon® BACC2 kit, GE Health Care 
Europe- Amersham) was added to the mixture, the system was allowed to mix for 5 
minutes and centrifuge at 350 rpm for 1 minute. This step extracted the DNA.  
 
Without disturbing the Nucleon Resin layer (brown in colour shown below), the upper 
solution was pipetted to another 1.5ml micro tube. Nine hundred micro liters (900 μl) 
of cold absolute ethanol (80% (v/v) Vietnam) was added and the tubes were inverted 
several times to precipitate the DNA. The DNA was then removed and allowed to air-
dry for 10 minutes. Later, the DNA was re-dissolved in sterile water. 
 
 
 
Figure 8. 1.5ml micro tube showing the separation of Nucleon Resin layer and DNA during 
extraction (Nucleon® BACC2 kit, GE Health Care   Europe- Amersham). Nine hundred micro 
liters (900 μl) of cold absolute ethanol (80% (v/v) Vietnam) was added to the upper solution and 
the tube was inverted several times to precipitate the DNA. The DNA was then removed and 
allowed to air-dry for 10 minutes. Later, the DNA was re-dissolved in sterile water. 
  36 
2.4.4 Genetic studies 
  
2.4.4.1 Gene amplification 
 
Due to limited budget for this study, genetic studies could only be done on frequent 
bleeding patients. Exon VIII (8) of the factor X gene was amplified using PCR and 
sequenced with Spectrumedix SCE 2410 Genetic analysis system (Spectrumedix ILL, 
USA). The PCR reaction was performed in a GeneAmp PCR system 9600 
thermocycler (PE Biosystems, Foster City, USA). Two sets of primers were used for 
the amplification of Exon 8. PCR for exonic 8A and 8B was performed in a 25 μl 
volume containing 300-500 ng of genomic DNA, 7.5 pmoles of each primer, 250 μM 
of each dNTPs, 0.87 units of Expand High Fidelity PCR system in supplied buffer-2 
(Roche Diagnostics, GmbH, Mannheim, Germany). The expand high fidelity PCR 
system is composed of thermostable Taq DNA polymerase with proofreading 
function. This results in PCR products with high yield, high fidelity and high 
specificity. PCR conditions for each fragment are detailed below. All reactions were 
carried out under the following conditions: 4 minutes at 95°C, 35 cycles at 95°C for 
30 seconds, 57°C for 1 minute, 72°C for 5 minutes with a final extension for 5 
minutes at 72°C (Jahandharan et al., 2005). 
 
 
 
 
Exon Forward primer     (5’-3’) Reverse primer     (5’-3’) Amplicon 
size (bp) 
Forward and 
reverse 
primers 
(pmoles) 
Final 
concentration 
of MgCl2  
(mM) 
Annealing 
temperature         
( °C) 
8A GATGTGCGAGAGCATGTCC CTTGAAGCGGGTGACGTG 496 7.5 1.5 57 
8B GCTACGACACCAAGCAGGAG GTATCTGGGGAAAGGAATGC 495 15 1.5 57 
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PCR product analysis 
 
PCR products were analysed by agarose gel electrophoresis. Subtyping was achieved 
through separation of different size PCR bands on a 2 ℅ agarose gel (50 ml of 0. 4 M 
Tris acetate EDTA, 1g of agarose and 1 μl of 10 mg/ml ethidium bromide ). The DNA 
was visualized by addition of 6 μl of 10 mg/ml ethidium bromide. A 50bp DNA was 
used as the molecular weight marker (50bp DNA molecular marker Roche 
Diagnostics, GmbH, Mannheim, Germany). The gels were visualized and 
photographed on UVP trans-illuminator using Grab IT annotating Grabber 2.51 
software (UVP (Inc), USA). 
 
 
2.4.4.2 DNA sequencing  
 
Purification of PCR products 
 
PCR products were purified using the QIAquick PCR purification kit (Qiagen, 
Germany) before the samples were sent for sequencing. The QIAquick purification kit 
is for direct purification of double or single stranded PCR product (100bp-10Kb) from 
amplification reactions. This kit is suitable for fast cleanup of up to 10 μg of DNA 
fragments from enzymatic reactions and agarose gels. Using proven microspin 
technology, the kit delivers highly concentrated purified DNA. 
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 Procedure 
 
Eight hundred micro liters (800μl) of buffer PB (guanidine hydrochloride, 
isopropanol) (Qiagen, Germany) was added to the PCR products and mixed by 
pipetting. This buffer dissolved the agarose gel. The solution was added to a QIA spin 
column placed in a 2ml collection tube. The column was then centrifuged at 13000 
rpm for 50 seconds. The filtrate was discarded and the column was placed back to the 
same collection tube. Seven hundred and fifty micro liters (750μl) of buffer PE 
(ethanol) (Qiagen, Germany) was added to the spin column to wash the samples and 
centrifuged at 13000 rpm for 1 minute. The filtrate was discarded and the spin column 
was placed back to the same tube and centrifuged for an additional 1 minute for 
complete removal of ethanol from buffer PE. The spin column was then placed in a 
clean 1.5ml microcentrifuge tube and 50μl of buffer EB (10 mM Tris-Cl, pH 8.5) 
(Qiagen, Germany) was added to elute the DNA. The purity of the eluted DNA was 
checked on a NanoDrop spectrophotometer. 
 
DNA sequencing 
 
The PCR products were sequenced on an automated Spectrumedix SCE 2410          
(Spectrumedix ILL, USA) from Inqaba Biotech (Pty) Ltd, South Africa. This 
automated sequencer, incorporates the ABI Big Dye terminator cycle sequencing kit 
version 3.1 (Applied Biosystem, Foster city, CA) with the primers. The reaction was 
carried out in a 20 μl reaction. Forward and reverse primers were the same as those 
used for PCR amplifications.  
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In brief, approximately 50-90 ng of PCR product was mixed with 5.0 μl of Terminator 
Ready Reaction mix (A,C,G and T-dye terminators; dNTPs, Tris-HCL (pH9.0), 
MgCl2, thermal stable pyrophosphatase and Amplitech DNA polymerase FS) 
(Biosystem, Foster city, CA), 2 μl of 5 X sequencing buffer and 3.2 pmol primer. 
Sequencing conditions were similar to the one used for gene amplification. Excess 
DyeDeoxy terminators were removed from the DNA sequencing products with 
Centri-Sep Spin columns (Biosystem, Foster city, CA). The purified products were 
dried in a speedivac at -60 °C and stored at -20 °C. Sequencing data was analysed 
with (MEGA) software version 4.0 (Tamura et al, 2007). Results were compared with 
FX sequence as reported in the GenBank database (GenBank accession no. M57285). 
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CHAPTER 3 
 
3. RESULTS 
 
3.1 Cytokine analysis 
 
The sample population consisted of fourteen (14) patients that were divided into two 
groups according to their families. Age, gender, factor X activity, clinical 
manifestations and cytokine profiles are shown in Table 3.1.1 and Table 3.1.2 
respectively. 
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Table 3.1.1: Coagulation factor X activity levels, clinical manifestations and 
cytokine profiles of the first factor X deficient family. 
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CFXD 1 42 M 35% Frequent 
bleeder 
 
70.72                   123.04 62.51 335.00 57.12 
CFXD 2 51 M 9% Infrequent 
bleeder 
 
0.01                      0.07 31.21 398.02 87.41 
CFXD3  83 M 44% Infrequent 
bleeder 
 
0.01                      0.03 31.20 278.01 86.21 
CFXD 4 34 M 3% Infrequent 
bleeder 
 
0.01                      0.10 43.23 550.00 79.31 
CFXD 5  40 M 43% Infrequent 
bleeder 
 
0.02                    0.01 48.22 665.01 91.21 
 
 
High levels of IL-1beta, TNF-alpha and IL-18 were noted in a frequent bleeding 
patient CFXD 1 compared to the other family members. These cytokines are reported 
to induce synovitis and lead into massive joint bleeding. High levels of IL-10 were 
noted in the entire infrequent bleeding patients. This cytokine was reported to inhibit 
the inflammatory synovitis and lessen the severity of joint bleeding. 
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Table 3.1.2: Coagulation factor X activity levels, clinical manifestations and 
cytokine profiles of the second factor X deficient family. 
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CFXD 6 26 M 
 
30% Infrequent 
bleeder 
 
0.02 0.07 160.01 43.12 98.3 
CFXD 7 18 M 
 
25% Infrequent 
bleeder 
 
0.01 0.06 850.03 40.23 89.47 
CFXD 8 41 F 
 
1% Frequent 
bleeder 
 
146.75 84.21 665.01 82.51 63.91 
CFXD 9 67 F 
 
36% Infrequent 
bleeder 
 
0.01 0.03 685.02 42.40 93.52 
CFXD10     
 
54 M 4% Infrequent 
bleeder 
 
0.01 0.09 278.21 42.72 88.34 
CFXD 11 28 F 50% Infrequent 
bleeder 
 
0.01 0.04 875.01 105.61 89.01 
CFXD 12 18 F 80% Infrequent 
bleeder 
 
0.01 0.07 555.10 65.23 93.12 
CFXD 13 14 M 4% Infrequent 
bleeder 
 
0.01 0.01 278.00 31.24 101.24 
CFXD 14 42 M 26% Infrequent 
bleeder 
 
0.10 3.29 398.00 98.33 87.23 
CFXD 15 34 F 22% Infrequent 
bleeder 
 
0.01 0.08 678.10 101.35 87.91 
CFXD 16 55 F 4% Frequent 
bleeder 
 
204.2 97.41 866.01 42.13 66.21 
 
Low levels of IL-1beta and TNF-alpha were observed in infrequent bleeding patients. 
High levels of IL-1beta, TNF-alpha were noted in CFXD 8 and CFXD 16. High levels 
of IL-10 were noted in all infrequent bleeding patients. No pattern was noted with   
IL-18 in both infrequent and frequent bleeding patients. 
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3.2 Genetic analysis 
 
The PCR results of the first and second amplicon fragment are shown in figure 9 and 
figure 10 respectively. These amplicons were carefully cut from the gel, purified with 
QIAquick PCR purification kit (Qiagen, Germany) and sequenced using the 
Spectrumedix SCE 2410 (Spectrumedix ILL, USA).Sequencing results are shown in 
figure 11 and figure 12 respectively. 
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                                  1           2            3              4            5 
 
Figure 9. PCR results showing the first portion of exon VIII (8A). The amplicon size was 496 bp.                      
Lane 1 represents CFXD1, lane 2 represents CFXD8, lane 3 represents CFXD16, lane 4 
represents the control and lane 5 represents the 50 bp DNA Ladder (50bp DNA molecular 
marker Roche Diagnostics, GmbH, Mannheim, Germany). 
 
 
 
 
 
 
 
  
 
496 bp 
 
300 bp 
 
1000 bp 
 
50 bp 
 
500 bp 
 
  45 
 
 
                                        1            2             3            4             5 
 
Figure 10. PCR results showing the second portion of exon VIII (8B). The amplicon size was 495 
bp. Lane 1 represents CFXD1, lane 2 represents CFXD8, lane 3 represents CFXD16, lane 4 
represents the control and lane 5 represents the 50 bp DNA Ladder (50bp DNA molecular 
marker Roche Diagnostics, GmbH, Mannheim, Germany). 
                      
 
 
 
50 bp 
 
1000 bp 
 
495 bp 
 
300 bp 
 
500 bp 
 
  46 
 
                                  240                         250                           260                              270                            280                           290                           300                             310                              
CONSENSUS          D F N Q T Q P E R G D N N L T R I V G G Q E C S D G E C P W Q A L L I N E E N E G D C G G T R L S E F Y I L T A A H C L Y Q A K R R K V R V G D R N T E Q E E 
CFXD 1               ● ● ● ● ● ● ● ● ● ● ● ●● ● ●● ● ●● ● ●● ● ●● ● ●● ● ●● ● ●● K●● ●●W● ●● ● ●● ● ●● ● ●● ● ●W● ● ●● ● ●● ● ●●●● 
CFXD 8               ● ● ● ● ● ● ● ● ● ● ● ●● ● ●● ● ●● ● ●● ● ●● ● ●● ● ●● ● ●● ● ●● ●●W● ● ●● ● ●● ● ●● ● ●● ●●● ● ●● ● ●● ●●●●●● 
CFXD 16             ● ● ● ● ● ● ● ● ● ● ● ●● ● ●● ● ●●P●● ● ●● ● ●● ● ●● ● ●● ●K●● ● ●● ● ●● ● ●● ● ●● ● ●● ● ●● ● ●● ● ●● ●●●●●●● 
 
 
                                     320                            330                          340                            350                           360                             370                             380                            390                              
CONSENSUS          G G E A V H G R W S S S T T G T K E T Y D F D I A V L R L K C P I T F R M N C A P A C L P E S D W R V T L M T Q K T G I V S F G R S H E K G R Q S T R L K M  
 
CFXD 1               ● ● ● ● ● ● ● ● ● ● ● ●● ● ●● ● ●● ● ●● ● ● ● ●● ● ●● ● ●● ● ●● ●● P● ● ●● ● ●● ● ●● ● ●● ● ● P● ● ●● ● ●● ●●●● 
CFXD 8               ● ● ● ● ● ● ● ● ● ● ● ●● ● ●● ● ●● ● ●● ●●●F ● ●● ● ●● ● ●● ● ●● ● ●● ● ●● ● ●● ● ●● ● ●● ● ●● ● ●● ● ●●●●●●● 
CFXD 16             ● ● ● ● ● ● ● ● ● ● ● ●● ● ●● ● ●● ● ●● ● ●  F ● ●● ● ●● ● ●● ● ●● ● ●● ● ●● ● ●● ● ●● ● ●● ● ●● ● ●● ● ●●● ●● ●  
 
 
Figure 11. Predicted amino acid sequence alignment of the three patients compared with their respective consensus sequence obtained from H. sapiens (GenBank 
accession no. M57285). The dotted line represents similarity with the consensus and the change in amino acid is presented. Multiple sequence alignment was 
performed with CLUSTALW file using the Mega 4 software (Tamura et al, 2007). 
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Differences were observed between the amino acid sequence of the three frequent 
bleeding patients and the consensus. In addition, a novel mutation Cys350Phe was 
detected in CFXD 8 and CFXD 16 (figure 12). This mutation is characterized by G>C 
change in position 350 (Andrea and Fatima 2008; ISTH factor X database, 2009; 
Vianello et al., 2003). Therefore, the severity of bleeding might be related with these 
changes. It is possible that after post translation processing the catalytic domains of 
these patients becomes inactive and destroyed in the plasma. This results in low factor 
X activity levels and contributes to the massive joint bleeding.  
 
3AR 
3A   
Axon 
 
                                        
Figure12. Nucleotide sequences showing G>C mutation that results into Cys350Phe mutation 
(Andrea and Fatima 2008; ISTH factor X database, 2009; Vianello et al., 2003). 3AR represents 
the reverse sequence, 3A represents the forwards sequence and axon represents the consensus 
sequence. 
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CHAPTER 4 
 
 
4. DISCUSSION AND CONCLUSION 
 
 
4.1 Cytokine analysis 
 
 
4.1.1 Cytokines and Clinical manifestations 
 
 
The present study has explored the association between cytokine profiles and the 
clinical manifestations of the two factor X deficient families. The high expression of 
IL-1beta and TNF-alpha in CFXD 1, CFXD 8 and CFXD 16 is consistent with 
ongoing joint inflammation in haemophilia. These cytokines are known to be involved 
in the acute inflammatory process leading to cellular infiltrate and joint swelling. This 
result in chronic synovitis and the creation of a vicious cycle of bleeding → synovitis 
→ bleeding (Ovlisen et al., 2009).The current data has supported our hypothesis that 
the intensity of bleeding from these patients was related to the expression of the two 
cytokines. This enhances the synovitis cycle and creates massive joint bleeding. 
 
Given the potential independent etiologic basis for pro-inflammatory cytokines, it 
would not be surprising if the source of the inflammatory cytokines generated in these 
patients were different. The source of IL-1beta in the inflamed joint may be generated 
from invading macrophages, or via local production from the fibroblast-like 
synoviocytes (FLS) (Hana et al., 2007; Kaneyama et al., 2002). One of the stimulants 
may also be a recently discovered cytokine, IL-32 which is expressed constitutively in 
FLS (Fukui et al., 2003; Joosten et al., 2006). 
 
  
 49 
The overwhelming down regulation of IL-1beta and TNF-alpha in infrequent bleeding 
patients appears to be related to the high expression of IL-10 and IL-1Ra. Therefore, 
the source for mediators of inflammation in these patients may be more dependent on 
the local production of anti inflammatory cytokines by cells residing within the joint 
and the external influx. IL-1beta may be produced locally within the joint by 
stimulated chondrocytes but, due to high expression of these anti-inflammatory 
cytokines, this inhibits the inflammatory synovitis and lessens the severity of joint 
bleeding. Once again, the current data seems to supports such evidence. 
 
There are ranging debates about the role of IL-18 during inflammatory synovitis. 
Most studies indicates that IL-18 plays an important role in synovitis and joint 
destruction via T cells and macrophages (Dai et al., 2004; Leo et al., 2004; Smeets et 
al., 2003). Most authors believe that IL-18 up regulates the production of IL-1beta and 
TNF-alpha, but it does not have a direct effect on FLS (Dai et al., 2004; Leo et al., 
2004; Smeets et al., 2003). It was demonstrated that high levels of IL-18 were 
associated with the production of IL-1beta and TNF-alpha .This was then found to 
result in chronic synovitis (Dai et al., 2004; Leo et al., 2004; Smeets et al., 2003). 
 
The current data has not found any association between the expression of IL-18 and 
the production of TNF-alpha and IL-1beta. This creates questions about the validity of 
this association. According to Kenji et al. (2001), it was not true to justify IL-18 as a 
pro inflammatory cytokine. It was shown that IL-18 is a unique cytokine that 
stimulates both pro and anti- inflammatory responses depending on the surrounding 
cytokines (Kenji et al., 2001). 
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It was found that stimulation with IL-12 and IL-18 was associated with the production 
of IFN-γ and other anti-inflammatory cytokines in a synergistic manner (Dong et al., 
2009). Moreover, naive T cells were found to produce both IL-4 and IL-13 in 
response to stimulation with IL-18 (Tomohiro et al., 1999). IL-4 and IL-13 are 
cytokines that are known to have suppressive effect on pro-inflammatory cytokines 
(Kenji et al., 2001; Nathan and denizot 1998). It was then concluded that the actions 
of IL-18 were influenced by the surrounding cytokines. In conditions with high 
expression of pro-inflammatory cytokines (IL-1beta and TNF-alpha), IL-18 was more 
likely to support the actions of pro-inflammatory cytokines, while in conditions with 
high expression of anti-inflammatory cytokines the opposite effect was expected 
(Kenji et al., 2001). 
 
The quantitative determination of IL-4, IL-3 and IL-12 are beyond the scope of this 
investigation, but it would have enabled means to assess the clear picture of IL-18 in 
these patients. It could be possible that the expression of IL-18 in frequent bleeding 
patients is associated with pro-inflammatory actions because of the high expression of 
IL-1beta and TNF-alpha. However, in infrequent bleeding patients IL-18 might 
support the actions of anti-inflammatory cytokines because of the high expression of 
IL-10 and IL-1Ra. This leaves an open field for research to predict the exact role of 
IL-18 in these patients. 
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4.1.2 Cytokines and Coagulation X factor levels 
 
In FXD, the bleeding diathesis stimulates the coagulation cascade to ensure the 
culmination of bleeding. The lack of factor X ensures the massive expression of tissue 
factor which could be stimulated by TNF-alpha and IL-1beta (Charles 2001; 
Emanuela et al., 1997; Sarah and Machin 2007). It was expected that patients with 
low factor X activity levels will present with high levels of the two cytokines to 
ensure the production of the tissue factor. However, the current data has showed no 
significant pattern between factor X activity levels and the expression of these two 
cytokines. Therefore, the patho-physiological mechanisms predisposing a particular 
individual to these inflammatory cytokines requires further elucidation. It could be 
possible that the discrepancy in the expression of these cytokines lies with the 
individual genotype in maintaining the balance between pro and anti -inflammatory 
cytokines (Figure 13). 
 
 
 
Figure 13. The outcome and severity of chronic synovitis is determined by the balance between 
destructive or pro-inflammatory and anti-inflammatory or regenerative signaling pathways 
(Rick et al., 2004). 
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The coagulation process is down regulated by inhibitors such as anti- thrombin, 
protein C and protein S (Charles 2001; Sarah and Machin 2007). Defects in these 
inhibitors often lead to a pro thrombotic status. Some studies have suggested that this 
status would change the clinical manifestation and make the bleeding tendency less 
severe (Escuriol et al., 2001; Nichols et al., 1996). Nichols et al. (1996) observed that 
haemophiliac patients with FV mutation had less severe phenotype. This mutation 
resulted in a lack of protein C and S thus creating the pro thrombin status. It was 
argued that the pro-thrombotic risk factors compensated for the low factor levels and 
result in more efficient thrombin generation and clot formation. This is one area that 
needs to be investigated in FXD populations (Nichols et al., 1996). 
 
4.2 Genetic analysis 
 
A number of substitutions of proline (P) residues to serine (S) were predicted in 
CFXD 1 and CFXD 16. According to Bereczky et al. (2008), differences associated 
with these changes include the lack of cleavage of factor X, altered orientation and a 
reduction in the catalytic efficiency toward the substrate prothrombin. It was 
suggested that substitution of proline (P) residue to serine (S) could be responsible for 
these multiple effects (Bereczky et al., 2008). It was unfortunate that without 
availability the three-dimensional structure of activated factor X, it was difficult for 
them to attribute these mutations (Bereczky et al., 2008). 
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A substitution of Aspartate (D) 282 was observed in CFXD 1 and CFXD 16. 
Molecular modelling studies have suggested that Aspartate (D) 282 is one of the fully 
buried residue at the centre of β-strand that is adjacent to the catalytic triad. (Fabrizio 
et al., 2001; James and uprichard 2002). It was suggested that a change in this residue 
might pertub the catalytic triad resulting in misfolded protein which will be destroyed 
in the plasma. (James and uprichard 2002).Therefore, the low levels of factor X 
activity in these two patients might result from these changes. 
 
A change in Arginine 287(R) was observed in CFXD 1 and CFXD 8. Arginine 287(R) 
is a highly solvent accessible residue. This residue is implicated in factor V binding 
during the activation of factor X (James and uprichard 2002; Marchettgi et al., 1995). 
It was suggested that the introduction of tryptophan (W) was unlikely to affect the 
conformation of the protein, but it may alter the electrostatic profile of activated factor 
X. This may in turn compromise the factor V binding (James and uprichard 2002). 
  
The Cys350Phe detected in both CFXD 8 and CFXD 16 is a novel mutation. This 
mutation is characterized by very low factor X levels which sometimes are not 
detectable in circulation. According to the molecular modeling study it was shown 
that Cys350 is positioned in the primary substrate binding pocket (Jayandharan et al., 
2005). The side chain of the substituted cystine was shown to cause defect in the 
substrate binding, leading to the loss of enzyme activity (Vianello et al., 2003). 
Therefore, despite the influence of cytokines, the severity of bleeding might be 
exerted by these mutations. 
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The goal of understanding the relationships between structural and functional aspects 
of factor X has been limited by the small number of reported factor X abnormalities 
(Millar et al., 2000). Investigation of the normal and abnormal variations in the factor 
X gene had been limited by the elucidation of restriction fragment length 
polymorphisms (Millar et al., 2000).Some preliminary studies have succeeded in 
characterizing mutations evolving from different regions of the factor X gene. 
However, much still needs to be done (ISTH factor X database, 2009). 
 
Based on structural homology of the vitamin K-dependent serine protease, naturally 
occurring mutations in the factor IX and prothrombin genes should complement our 
understanding of the structure-function relationships of factor X (Millar et al., 2000). 
The predicted amino acids changes reported in this study produced no significant 
clinical characterization of these patients. However, these changes provide a model 
for future structure-function studies of factor X and new insights into the molecular 
bases of FX deficiency. 
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4.3 Limitations of the study 
 
The results for the cytokine analysis were extrapolated from the standard curve. It was 
a challenge to extrapolate precise values that were below the zero standard. Cytokine 
secretion is influenced by the number of factors such as diet and physical activity. It 
would have been more appropriate to have fresh samples from these patients at least 
every month. This would have help in assessing the consistency of the current results. 
However, due to on going migration of some family members, this was an impossible 
mission to embark on. 
 
Forward and reverse sequences for each of the segments sequenced were checked for 
background noise at the beginning and end of the sequence. Those parts of the 
chromatogram that did not show well defined peaks were edited before the sequences 
were analyzed. This has resulted into sufficient amount of data being lost. 
 
The sequencing was performed only on frequent bleeding patients. It would have been 
better to sequence the whole 27 kb in all the participants. This would have enabled us 
to compare the mutations between and within the family members. In future, more 
funding should be invested to fully characterize these patients. It is still possible that 
the discrepancy of the bleeding series might be explained by individual mutations. 
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4.4 Conclusion 
 
Large heterogeneity in bleeding pattern and arthropathy is observed among patients 
with coagulation disorders. Because the distinction of phenotypes has implications for 
both clinical practice and basic science, it is an important subject for study (Pencharz 
2006). Understanding the reasons for the heterogeneity in clinical manifestations can 
give clues that can lead to identifying factors which influence the final haemostasis in 
FXD. Although there seems to be an overall acceptance that there is a large clinical 
heterogeneity among patients, no data is available to explain how to identify patients 
at different bleeding risk. 
 
The results of this current study have shown that levels of IL-1beta and TNF-alpha are 
high in frequent bleeding patients compared to infrequent bleeding patients with 
Factor X deficiency. However, much work is still needed. This was a small study 
intended to elucidate the cytokine profiles of the two families with FXD. More large 
studies are still needed to justify the statistical difference on these cytokines. From the 
evidence presented, one might conclude that the origin of the heterogeneity of clinical 
manifestations in FXD is multifactorial. Cytokines such as TNF-alpha and IL-1beta 
seem to be involved in the induction and the perpetuation of synovitis. This leads into 
circle of massive joint bleeding.  
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High levels of IL-10 in the entire infrequent bleeding patients suggest that these 
patients might be switching on genes for anti-inflammatory cytokines. This inhibits 
the inflammatory synovitis and lessens the frequency and severity of joint bleeding. 
Based on these findings, it could be suggested that the administration of anti-
inflammation drugs might be of benefit to the bleeding tendencies of these patients. 
 
The differences observed between the amino acid sequence of the FX protein of the 
three patients and the consensus may provide a model for future structure-function 
studies of FX. The severity of bleeding might be related to these structural changes. It 
might be possible that after post translational processing the catalytic domains of 
these patients becomes inactive and destroyed in the plasma. This results in low factor 
X levels which contributes to the increased bleeding frequency.  
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